Enoxaparin: A pharmacologic and clinical review

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 1157-1170

  Iqbal, Zafar ^a   Cohen, Marc ^a,b  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; anticoagulant; LMWH; thromboembolism

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OTAMIXABAN; PLACEBO; RIVAROXABAN; STREPTOKINASE; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CATHETER THROMBOSIS; CLINICAL ASSESSMENT; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HIP ARTHROPLASTY; HUMAN; IMMUNOGENICITY; KNEE ARTHROPLASTY; LOADING DRUG DOSE; LUNG EMBOLISM; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VASCULAR PATENCY; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; ENOXAPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 79953856301     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.570261     Document Type: Review

References (105)

1. Rosamond W, Flegal K, Furie K, et al. Heart Disease and Stroke Statistics-2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117(4):e25-146
2. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;12:585-93 (Pubitemid 28144815)
3. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl):454-545S
4. Spyropoulos AC, Hurley JS, Ciesla GN, et al. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002;122:108-14 (Pubitemid 34754149)
5. Adams R, Friday G, Furie K, et al. Heart disease and stroke statistics: 2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Committee: American Heart Association, Dallas, Texas. Circulation 2006;113:85-151
6. Singh KP, Roe MT, Peterson ED, et al.; for the CRUSADE Investigators. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein Iib/IIIa inhibitors: results from the CRUSADE initiative. J Thromb Thrombolysis 2006;21:211-20 (Pubitemid 43676777)
7. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev 2010;2:CD003747
8. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133:160S-98S (Pubitemid 351892967)
9. Cheng S, Morrow DA, Sloan S. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation 2009;119:1195-202
10. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133:234-56S
11. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42). Lancet 2009;374:787-95
12. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85
13. Mega J, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double blind, phase II trial. Lancet 2009;374:29-38
14. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Eng J Med 2010;363:2487-98
15. Study of apixaban for the prevention of thrombosis-related events in patients with acute medical illness (ADOPT). Available from: http://clinicaltrials.gov/ct2/show/NCT00457002 [Last accessed 5 December 2010]
16. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. Available from: http://clinicaltrials.gov/ ct2/show/NCT00633893 [Last accessed 5 December 2010]
17. Bauersachs R, Berkowitz SD, Brener B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Eng J Med 2010;363:2499-510
18. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for hromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 2009;373:1673-80
19. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-9
20. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63 (Pubitemid 37430344)
21. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007;298:2497-506 (Pubitemid 350223536)
22. White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-63 (Pubitemid 34008652)
23. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30 (Pubitemid 351724451)
24. Spencer F, Liu L, Zhang Q, et al. Enoxaparin suppresses platelet-dependent thrombin generation in vivo among patients with unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1997;29(Suppl A):304A
25. Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998;56:259-72 (Pubitemid 28391521)
26. Fareed J, Jeske W, Hoppensteadt D, et al. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998;82(5B):3-10L
27. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995;6(Suppl 1):S57-64
28. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995;29(9):892-905
29. Fareed J, Walenga JM, Hoppensteadt D, et al. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemost 1989;15:440-63 (Pubitemid 19265848)
30. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6 (Pubitemid 28067310)
31. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-8
32. Currier JW, Pow TK, Haudenschild CC, et al. Low molecular weight heparin (enoxaparin) reduced restenosis following angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:118-25B.
33. Erratum in: J Thromb Thrombolysis 2009;28:229
34. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90:908-14 (Pubitemid 24242761)
35. Kiesz RS, Buszman P, Martin JL, et al. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial. Circulation 2001;103:26-31
36. Martin JL, Fry ET, Amrtin T, et al. The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study). J Thromb Thrombolysis 2009;28:224-8
37. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins: dalteparin, enoxaparin and nadroparin: administered sub-cutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-40
38. Eriksson BI, Soderberg K, Widlund L, et al. A comparative study of three low molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401
39. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985:39:631-6 (Pubitemid 15228564)
40. Laforest MD, Colas-Linhart N, Guiraud-Vitaux F, et al. Pharmacokinetics and biodistribution of technetium 99m la-enoxbelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol 1991;77(2):201-8
41. Cohen M, Demers C, Gurfinkel E, et al.; for the ESSENCE Study Group. Acomparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52 (Pubitemid 27333045)
42. Antman EM, Mccabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601 (Pubitemid 29477267)
43. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 1 B, ESSENCE meta-analysis. Circulation 1999;100:1602-8 (Pubitemid 29477268)
44. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-34 (Pubitemid 37281706)
45. Blazing MA, de Lemos JA, White HD, et al.; A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomised controlled trial. JAMA 2004;292:55-64. (Pubitemid 38923794)
46. Erratum in: JAMA 2004;292:1178
47. Ferguson JJ, Califf RM, Antman EM, et al.; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomised trial. JAMA 2004;292:45-54
48. Cohen M, Levine GN, Pieper KS, et al. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv 2010;75:928-35
49. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomised to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89-96 (Pubitemid 38923799)
50. Yusuf S, Mehta SR, Chrolavicius S, et al.; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76
51. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute oronary syndromes undergoing percutaneous coronary intervention. Results from the OASIS-5 trial. J Am Coll Cardiol 2007;50:1742-51 (Pubitemid 47600591)
52. Simoons ML, Krzeminska-Pakula M, Alonso A, et al.; AMI-SK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282-90 (Pubitemid 35238510)
53. Ross AM, Molhoek P, Lundergan C, et al.; HART II Investigators. Randomised comparison of a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52 (Pubitemid 32738517)
54. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIREThrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-9 (Pubitemid 34298606)
55. Erratum in: Circulation 2002;105:2799
56. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13
57. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomised trial in acute myocardial infarction. Circulation 2003;108:135-42 (Pubitemid 36871293)
58. Elliott M, Antman MD, Morrow DA, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-88
59. Gibson CM, Murphy SA, Montelescot G, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007;49:2238-46 (Pubitemid 46856824)
60. Available from: http://www.escardio.org/congresses/esc-2010/congress- reports/Pages/707-4-ATOLL.aspx? hit=dontmiss#presenter [Last accessed 27 January 2011]
61. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007;28:2077-86 (Pubitemid 47517436)
62. Zidar JP. Low-molecular-weight heparins in coronary stenting (the ENTICES trial). enoxaparin and ticlopidine after elective stenting. Am J Cardiol 1998;82:29-32L
63. Kereiakes DJ, Grines C, Fry E, et al.; NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-8 (Pubitemid 33759464)
64. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17 (Pubitemid 44343544)
65. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925-9 (Pubitemid 16023679)
66. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-8 (Pubitemid 26254196)
67. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. Ann Intern Med 1991;114:545-51
68. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-10 (Pubitemid 19023731)
69. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a lowmolecular-weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg Am 1994;76-A:3-14 (Pubitemid 24081799)
70. Fauno P, Suomalainen O, Rehnberg V, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular weight heparin. J Bone Joint Surg Am 1994;76-A:1814-18
71. Spiro TE, Colwell CW, Bona RD, et al. Enoxaparin versus unfractionated heparin for prevention of venous thromboembolic disease after knee replacement surgery. Chest 1994;106(Suppl 2):48S
72. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomised, double-blind trial comparing enoxaparin with warfarin. Ann Int Med 1996;124:619-26
73. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75 (Pubitemid 351930851)
74. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
75. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86 (Pubitemid 351930852)
76. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
77. Lassen MR, Gallus AS, Pineo GF, et al. The ADVANCE-2 study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement (abstract LB-MO-005). J Thromb Haemost 2009;7(Suppl 2):1204
78. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56 (Pubitemid 47393577)
79. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85 (Pubitemid 47617868)
80. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
81. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
82. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 12 Jan 2011;105 doi:10.1160/TH10-10-0679
83. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800 (Pubitemid 29420474)
84. Kleber FX, Witt C, Vogel G, Koppenhagen K. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-21 (Pubitemid 36403489)
85. Bergmann J-F, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996;76:529-34 (Pubitemid 26372006)
86. Lederle FA, Sacks JM, Fiore L, et al. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 2006;119:54-9 (Pubitemid 43117467)
87. Sherman DG, Albers GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007;369:1347-55 (Pubitemid 46621092)
88. Samama M, Bernard P, Bonnardot JP, et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128-31 (Pubitemid 18078528)
89. Nurmohamed MT, Verhaeghe R, Haas S, et al. A comparative trial of a low molecular weight heparin (enoxaparinversus standardheparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995;169:567-71
90. Gazzaniga GM, Angelini G, Pastorino G, et al. Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group. Int Surg 1993;78:271-5 (Pubitemid 23300644)
91. Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099-103
92. Simonneau G, Laporte S, Mismetti P, et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 2006;4:1693-700 (Pubitemid 44144795)
93. Baykal C, Al A, Demirtas E, et al. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaec Oncol 2001;22:127-30 (Pubitemid 32963064)
94. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecularweight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6 (Pubitemid 23205852)
95. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81 (Pubitemid 26079800)
96. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15 (Pubitemid 28135667)
97. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202
98. Rao SV, O'Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006;47:809-16 (Pubitemid 43243106)
99. Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998;23(6 Suppl 2):164-77 (Pubitemid 28531569)
100. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin induced thrombocytopenia: review and update. Thromb Res 2006;118:165-76
101. Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009;302:2458-64
102. Thompson CA. Am J Health Syst Pharm 2010;67:1492. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/ howdrugsaredevelopedandapproved/approvalapplications/ abbreviatednewdrugapplication andagenerics/default.htm
103. Available from http://www.fda.gov/drugs/developmentapprovalprocess/ howdrugsaredevelopedandapproved/approvalapplications/ abbreviatednewdrugapplication andagenerics/default.htm [Last accessed on 29 March 2011]
104. Gomes M, Ramacciotti E, Litinas E, Fareed J. Concerns on generic enoxaparin use in acute coronary syndrome. Arq Bras Cardiol 2010;95:551-2
105. Gomes M, Ramacciotti E, Hoppensteadt D, et al. An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers. Clin Appl Thromb Hemost 2011;17(1):66-9